Yang Yang

TL;DR: The results reveal that MERS-CoV has adapted to use human receptor and cellular proteases for efficient human cell entry, whereas HKU4 can potentially follow-up and also infect human cells, and suggest that DPP4-recognizing bat coronaviruses threaten human health because of their spikes’ capability to adapt to human cells for cross-species transmissions.

TL;DR: This review illustrates MERS-CoV S protein’s structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS- coV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides.

TL;DR: The results support the idea of bats as an evolutionary origin for PEDV, implicate P EDV as a potential threat to other species, and suggest antiviral strategies to control its spread.

TL;DR: A neutralizing monoclonal antibody, designated Mersmab1, is developed, which potently blocks MERS-CoV entry into human cells and can also serve as a useful tool to guide the design of effective MSPV vaccines.

TL;DR: Structural analysis suggests that S377-588-Fc contains the stably folded RBD structure, the full receptor-binding site, and major neutralizing epitopes, such that adding non-neutralizing structures to this RBD fragment diminishes its neutralizing potential.